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The epidermal growth factor receptor (EGFR) is a validated target in squamous cell carcinoma (SCC) of the head and neck. Most
patients, however, do not respond or develop resistance to this agent. Mammalian target of rapamycin (mTOR) is involved in the
pathogenesis of SCC of the head and neck (SCCHN). This study aimed to determine if targeting mTOR in combination with EGFR is
effective in SCC, and to develop early pharmacodynamic markers of efficacy. Two SCC cell lines, one resistant (HEP2) and one of
intermediate susceptibility (Detroit 562) to EGFR inhibitors, were xenografted in vivo and treated with an mTOR inhibitor
(temsirolimus), an EGFR inhibitor (erlotinib) or a combination of both. Temsirolimus exerted superior growth arrest in both cell lines
than erlotinib. The combined treatment resulted in synergistic antitumor effects in the Detroit 562 cell line. Immunohistochemical
assessment of pharmacodynamic effects in fine-needle aspiration (FNA) biopsies early after treatment using phospho MAPK,
Phospho-P70 and Ki67 as end points demonstrated pathway abrogation in the Detroit 562 tumours treated with the combination,
the only group where regressions were seen. In conclusion, an mTOR inhibitor showed antitumor activity in EGFR-resistant SCC cell
lines. Marked antitumor effects were associated with dual pathway inhibition, which were detected by early FNA biopsies.
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Squamous cell carcinoma (SCC) of the head and neck (SCCHN) is
the sixth most common cancer in the developed world, affecting
nearly 44000 patients and causing 11000 deaths each year in the
US alone (Jemal et al, 2006). The epidermal growth factor
receptor (EGFR) is a validated target in SCC of the head and neck
(Bonner et al, 2006). Erlotinib (Tarceva; OSI Pharmaceuticals,
Uniondale, NY, USA) and gefitinib (Iressa; Astrazeneca Inc.,
Willmington, DL, USA) are quinazoline derivatives that reversibly
inhibit the tyrosine kinase (TK) of EGFR, showing in vitro and in
vivo activity in SCCHN cell lines (Amador et al, 2004; Jimeno
et al, 2006) as well as in phase II clinical trials (Soulieres et al,
2004; Kirby et al, 2006). Tumour responses induced by these
agents are, however, infrequent and transient and even sensitive
patients rapidly develop secondary resistance. Thus, developing
therapeutic alternatives for such patients is a necessity. The
predominant mechanism underlying resistance to these agents
is unknown. Failure of one single strategy to fully inhibit the
pathway has been suggested and, in fact, dual targeting of the
EGFR results in improved antitumor effects in preclinical models
of SCC of the head and neck (Huang et al, 2004; Matar et al, 2004;
Jimeno et al, 2005). Another hypothesis is that persistent
activation of downstream pathways abrogates the effects of the
agents. Thus, one attractive approach is to combine EGFR
inhibitors with other signalling inhibitors targeting downstream
pathways.
It has recently been shown that SCC have elevated levels of Akt
activation (Amornphimoltham et al, 2004). In other preclinical
models such persistent activation of Akt has been linked to
resistance to EGFR inhibitors (Bianco et al, 2003). Furthermore, a
substantial body of preclinical studies suggest that tumours with
persistent Akt activation have heightened responses to inhibition
of the mammalian target of rapamycin (mTOR) (Neshat et al, 2001;
DeGraffenried et al, 2004; Gera et al, 2004). A recent study in SCC
cell lines demonstrates that inhibition of mTOR induces activation
of Akt and results in antitumor effects in this tumour type
(Amornphimoltham et al, 2005). In this model, as well as in other
disease types such as pancreas cancer (Bruns et al, 2004), the
antitumor effects of mTOR inhibitors appear to be in part related
to their antiangiogenic effects. In our previous work, we have
determined the susceptibility of a set of SCC cell lines both in vitro
and in vivo to EGFR inhibitors (Amador et al, 2004; Jimeno et al,
2006). In the current work, we tested whether mTOR inhibi-
tion with temsirolimus (Wyeth, Madison, NJ, USA) alone and
in combination with erlotinib would be efficacious in those
EGFR-resistant SCC in vivo models. We investigated the utility
of fine-needle aspiration (FNA)-based early assessment of
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spharmacodynamic response by immunohistochemistry assessing
both proximal Phospho-MAPK (pMAPK) and phospho-P70 (pP70)
and distal (Ki67) markers. These early biopsies were also used to
investigate changes in the expression profile of relevant genes
potentially related to angiogenesis and efficacy of EGFR and mTOR
inhibitors.
MATERIALS AND METHODS
Drugs
Erlotinib was provided by OSI Pharmaceuticals (Uniondale, NY,
USA). Temsirolimus was provided by Wyeth (Madison, NJ, USA).
Cell lines and in vitro culture conditions
The cell lines used in this study (HEP2 and Detroit 562) were
obtained from the American Type Culture Collection (Manassas,
VA, USA), and are derived from cervical (HeLa contaminant) and
head and neck squamous carcinomas, respectively. These cell lines
were used based on our prior knowledge of their sensitivity to
erlotinib as well as the existing information with mTOR inhibitors
in the model. The cell lines were grown in six-well plates with
RPMI media supplemented with 10% fetal bovine serum (FBS) and
1% penicillin/streptomycin (growth media (GM). When 50–60%
confluency was reached, they were serum starved overnight, after
which they were exposed to (1) serum-starved media for 2h and
30min, (2) serum-starved media for 30min followed by GM for 2h,
(3) serum-starved media plus erlotinib (10mM) for 30min followed
by GM plus erlotinib for 2h, (4) serum-starved media plus
temsirolimus (10mM) for 30min followed by GM plus temsirolimus
for 2h and (5) serum-starved media plus the combination of
erlotinib (10mM) plus temsirolimus (10mM) for 30min followed by
GM plus erlotinib plus temsirolimus for 2h. After this the cells were
washed twice with chilled PBS, lysis buffer was added to the plates
and the cells were scraped for protein extraction. An identical
experimental set was lysed directly from the tissue culture dish with
RLT (Qiagen, Valencia, CA, USA) for RNA extraction.
In vivo growth inhibition studies
Six-week-old female athymic nude mice (Harlan, IN, USA) were
used. 2 10
6 HEP2 and Detroit 562 cells were injected sub-
cutaneously in each flank. Tumours were allowed to grow until
reaching 200mm
3, at which time mice were randomized in the
following four groups of treatment, with five to six mice (10
evaluable tumours) in each group: (1) control, (2) erlotinib
50mgkgday
 1 i.p., (3) temsirolimus 20mgkgday
 1 i.p., and (4)
erlotinib plus temsirolimus at the above doses. Treatment was
given for 28 days. Mice were monitored daily for signs of toxicity
and were weighed three times per week. Tumour size were
evaluated two times per week by caliper measurements using the
following formula: tumour volume¼(length width
2)/2. Relative
tumour growth inhibition was calculated by relative tumour
growth of treated mice divided by relative tumour growth of
control mice (T/C).
FNA biopsies
Fine needle aspirations (FNAs) on mice were performed according
to standard cytopathologic practice under inhaled general
anaesthesia (isofluorane) using 10cm
3 syringes and 25-gauge
needles. During each FNA procedure, the first pass was smeared
onto glass slides and used for morphologic analysis, (DiffQuikt
and Papanicoloau), the second and third passes were harvested in
RLT buffer for RNA analysis, and the fourth and fifth passes in
formalin for immunohistochemical purposes. Six tumours per
treatment arm were biopsied at baseline and after 7 days of
therapy.
Western blot analysis
Equal amounts of protein were resolved on 10% polyacrylamide
gels. Gels were transferred onto nitrocellulose membranes that
were incubated overnight at 41C with antibodies against phospho-
EGFR, total EGFR, pMAPK, total MAPK, phospho-Akt, total Akt,
pP70, total P70 (Cell Signaling Technology, Beverley, MA, USA)
and actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA). The
immunoreactive proteins were detected using the enhanced
chemiluminescence method (Amersham, Piscataway, NJ, USA).
RNA extraction
For RNA extraction from the FNA samples, two passes from the
FNA were put in RLT lysis buffer (Mini RNeasy, Qiagen) and total
RNA was extracted using the Rneasyt Mini Kit (Qiagen). RNA
was transcribed into cDNA by reverse transcription by priming
with random hexamers (M-MLTV, Promega, Madison, WI, USA).
The excess hexamers were removed using a column-based clean-
up kit (Qiagen).
Quantitative real-time RT–PCR analysis
Samples were analysed in a blinded manner. For c-fos, egfr and
HIF-1alpha determination on in vitro samples and FNAs from
mice tumours, quantitative PCR was performed on an MX3000p
thermal cycler (Stratagene, Lajolla, CA, USA) using SYBR green
dye method to track the progress of the reactions with ROX dye
added as reference. Beta-Globin DNA specific primers were used to
test DNA contamination for each sample type. Three housekeeping
genes (HPRT, UBC and SDHA) were run in parallel with test genes.
The amount of change in the target gene between the control and
experimental conditions was found by comparing the threshold
cycle (Ct) of the target gene to the geometric mean of the Ct’s of
the housekeeping genes. The geometric mean of the Ct’s of each of
the housekeeping genes, and a change in Ct (delta Ct), between
conditions were calculated (dCtHouskeeping¼(CtHPRT*CtUBC*CtSD-
HA)control (CtHPRT*CtUBC*CtSDHA)exp). The change in Ct for the
target gene was calculated directly from Ct under each condition
(dCttarget¼(Cttarget)control (Cttarget)exp). The efficiency of the
housekeeping genes raised to their dCt divided by the efficiency
of the target gene raised to its dCt gave a ratio between the control
and experimental conditions normalised to the housekeeping
genes (Ratio¼ETarget
dCtTarget/EHousekeeping
dCtHousekeeping, where E is the Primer
efficiency and Ct is the Threshold cycle).
Immunohistochemical analysis
The pathology team was blinded for treatment allocation and
efficacy of the samples. Five-micrometre formalin-fixed paraffin
cuts were used for Ki67 staining that was performed following the
manufacturer’s instructions (08-0156; Invitrogen, Carlsbad, CA,
USA), and scored as percentage staining nuclei. Phospho-Thr202/
Tyr204 MAPK (4376; Cell signaling Technology, Beverly, MA,
USA) and phospho-p70/S6K (9206; Cell signaling ) staining was
performed using citrate-steam recovery, followed by Catalyzed
Signal Amplification II biotin-free tyramide kit (DAKO, Carpinteria,
CA, USA). Both the intensity (0, 1þ,2þ,3þ) and the percentage
(0–100%) of cells positive were considered. Three tumours
per treatment group were analysed. For statistical analyses, an
index of intensity percentage was calculated. CD31 staining
(550274; BD Pharmingen) was performed on zinc-fixed tissue
(51-7538KZ; BD Pharmigen). Two methods for vessel quantifica-
tion were used. First, microvessel density (MVD) was scored
according to the standard methods (Weidner et al, 1991).
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sBriefly, four areas per tumour were chosen and microvessel
per high-power field (HPF;  200) were counted. Second, we
developed a novel scoring system based on quantifying mouse
vessel invasion of the xenografts from the capsule. This was scored
according to the following: (1) Capillaries in the pseudocapsule
only, surrounding the tumour less than entire circumference. (2)
Capillaries in the pseudocapsule only, surrounding the entire
circumference of the tumour. (3) Capillaries in less than 50% of the
deeper stroma, but not extending to the tumour centre. (4)
Capillaries in more than 50% of the deeper stroma, but not
extending to the tumour centre. (5): Capillaries throughout the
tumour, including the centre. Six tumours per treatment group
were analysed.
Statistics
The comparisons between means and proportions obtained from
the biologic studies were carried out using Student’s t-test and w
2
method, respectively.
RESULTS
Pathway modulation analysis
We first profiled the selected cells lines in vitro to determine the
impact of the drugs in the activation of signalling pathways in this
model (Figure 1). In Detroit 562, erlotinib alone inhibited MAPK
activation and reduced the activation of Akt and P70. Temsiro-
limus predominantly inhibited P70 and induced no effects in the
phosphorylation of MAPK and/or Akt. The combined treatment
completely abrogated pMAPK, and significantly inhibited Akt
phosphorylation. HEP2 responded similarly but the degree of
inhibition was lower. Erlotinib alone had minimal effects in the
signalling pathways assessed; temsirolimus, however, induced Akt
activation and blocked P70, and the combination exerted increased
inhibition of pMAPK with a clear abrogation of temsirolimus-
induced Akt activation in this cell line.
In vivo growth inhibition analysis
The in vivo data are summarised in Figure 2. In HEP2, considering
the growth of the control group from treatment commencement to
the end of the experiment after 21 days as a 100% growth, erlotinib
alone did not delay growth significantly, reaching 56% of the
control volume by 21 days (Figure 2A). Temsirolimus slowed
growth to 32%, and the combination to 22% of the control group.
This represents an average tumour size of 230 and 191% compared
to the initiation of the experiment for the latter two treatment
groups, respectively.
In Detroit 562, erlotinib alone delayed growth to 34% of the
control volume by 21 days (Figure 2A), which corresponds to a
198% growth from the start of the trial. Temsirolimus slowed
growth to 13%, and the combination achieved a  18% of the
control group, representing a final tumour size of 136% for
temsirolimus and a decrease to 49% of the initial volume in
the combination arm (the only where actual tumour regressions
were seen).
Tumour immunohistochemical analysis
In each xenograft model, 16 tumours (four per treatment arm)
were followed by FNA at baseline and on day 7 of treatment for
immunohistochemical analysis. The results are shown in Figure 3.
In the comparison of the baseline FNA samples, the proliferation
index Ki67 was higher in HEP2 than in Detroit 562 tumours (91 vs
74%, P¼0.041), whereas the activation status index (intensity 
percentage) of MAPK was higher in Detroit 562 tumours (60 vs
119, P¼0.018). This was related to a higher percentage of cells
staining positive (24 vs 49%, P¼0.038), as the intensity in both
groups was similar. Phospho-P70 staining index was high in both
pP70
pAkt
MAPK
pMAPK
Growth media
Erlotinib
Temsirolimus
Akt
P70
Actin
−− ++
+
++ + +
++ +
++ + + + +
−− − − − −
−− − −−−
Detroit 562 HEP2
Figure 1 Analysis of the pathway activation profile after exposure to the study drugs. Cells were serum-starved overnight, after which they were
preincubated with erlotinib (10mM), temsirolimus (10mM) and the combination of both (10mM) followed by GM containing the same drugs. The experiment
was controlled by a continuously serum starved group, and a group that received GM without preincubation with any drug. In Detroit 562 erlotinib was able
to decrease pMAPK, although only the combination abrogated its activity completely. On the other hand, the effect in HEP2 was much less apparent.
Phospho-Akt was significantly abrogated in Detroit 562 by erlotinib-containing arms (particularly the combination), but not by temsirolimus, indicating a
more downstream level of inhibition. On the other hand, in HEP2 cells lower levels of pAkt were observed at baseline, no significant increase was seen upon
exposure with GM, and no inhibition was seen after erlotinib treatment. However, a clear upregulation was observed when treated by temsirolimus alone;
even more notably, this upregulation was not documented when both erlotinib and temsirolimus were combined. Inhibition of pP70 was seen in Detroit 562
and HEP2 cells after erlotinib and more markedly after temsirolimus or the combination.
Dual EGFR and mTOR targeting in SCC
A Jimeno et al
954
British Journal of Cancer (2007) 96(6), 952–959 & 2007 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
scell lines and showed no differences (274 vs 253, P¼0.31)
(Figure 3A).
On day 7 after treatment, neither Ki67 nor p-MAPK showed a
decrement in the HEP2 cell line. Phospho-P70 decreased mildly
(15 and 25%) after single-agent temsirolimus and the combined
regimen, respectively. In Detroit 562 tumours, Ki67 and pMAPK
only decreased significantly (450%) after combination therapy.
Phospho-P70 decreased after single-agent temsirolimus but more
dramatically with the combined therapy (40 and 60%, respectively)
(Figure 3B and C).
Therefore, FNA on day 7 was able to predict in both groups the
activity (or lack of) of the different agents by day 21. A significant
decrease in all three markers was only achieved in the combination
arm in the Detroit 562 cell line, and it was the only arm where
actual tumour regression was observed. Tumour stability (ob-
served in Detroit 562 treated with temsirolimus, and in HEP2
treated with temsirolimus and the combination) was heralded by
modest (o50%) decreases in pP70 staining index.
Tumour gene expression analysis
In each xenografted cell line, 24 tumours (six per treatment arm)
were followed by FNA at baseline and on day 7 of treatment for
gene expression analysis. The gene expression RT–PCR analysis
of the baseline FNA samples showed that HIF-1a mRNA
expression was nonsignificantly lower in HEP2 than in Detroit
562 tumours (7.9 vs 15.1 (arbitrary units), P¼0.064), whereas
there was no difference in c-fos (432 vs 708, P¼0.39) or EGFR
mRNA (6.4 vs 8.5, P¼0.41). When days 0 and 7 were compared,
HIF-1a mRNA increased two- and fourfold in HEP2 and Detroit
562 control tumours, respectively. C-fos levels increased twofold
in Detroit 562 control tumours, whereas no significant change
was documented in c-fos in HEP2, or in EGFR mRNA levels in
either of the two models. In HEP2 tumours, HIF-1a increased
after treatment with erlotinib, did not change with temsirolimus
and decreased three-fold in the combined arm. In Detroit
562, HIF-1a did not change with any single agent, but decreased
eight-fold in the combined arm. As previously described in
similar models (Jimeno et al, 2006), c-fos levels were not
suppressed by erlotinib in either HEP2 or Detroit 562 xeno-
grafts (data not shown). Epidermal growth factor receptor mRNA
levels increased in response to erlotinib in the resistant HEP2,
whereas did not change in the intermediately sensitive Detroit
562, in line with previous reports (data not shown) (Jimeno
et al, 2005).
Angiogenesis evaluation
Tumours were blindly examined for vessels by CD31 staining. The
standard MVD showed no significant changes between treatment
groups in HEP2 (Figure 4A). In Detroit 562 there was a higher
density of vessels than in HEP2. Single-agent erlotinib or
temsirolimus administration failed to induce any significant
changes in MVD. However the tumours treated with the
combination presented a trend towards lower MVD count
compared with control tumours (24 vs 43 vessels/HPF, respec-
tively; P¼0.068). Then we implemented a novel scoring system
that accounted for the pattern of microvessel invasion in the
tumours. In HEP2 there were again no significant differences
between treatment groups, as depicted in Figure 4B and C. All
Detroit 562 tumours assessed presented vessels in the periphery/
pesudocapsule of the tumour; however, the intratumor growth
varied significantly between treatment groups. Most of the control
tumours had widespread vessels reaching the centre of the tumour.
However, the temsirolimus but more importantly the erlotinib plus
temsirolimus group had a decrement in vessel intratumor growth.
Half of the tumours in the latter group showed no evidence of
vessel budding from the capsule inside the tumour, and none
of the tumours treated with the combination had vessels reaching
the centre.
DISCUSSION
There is increasing interest in combining signalling inhibitors
in cancer treatment. This study explored if combining treatment
with an EGFR and an mTOR inhibitor in an SCC model with
intermediate susceptibility to EGFR inhibition. The results show
that an mTOR inhibitor alone was superior to an EGFR inhibitor in
this model. In addition, the combined treatment was clearly
superior in one cell line but not the other with a profound tumour
regression elicited in the Detroit 562 line. Fine-needle aspiration
aspirate tumour biopsies performed on day 7 after treatment
showed greater pathway and angiogenesis modulation in the
combined treatment that accurately predicted the tumour growth
inhibition observed on day 21.
The analysis of pathway activation showed an upstream
activation in Akt induced by mTOR inhibition in the EGFR-
resistant cell line; other groups have previously described this
phenomenon (O’Reilly et al, 2006). Those authors suggest that cells
with constitutive activation of mTOR have a feedback down-
regulation of receptor TK signalling leading to Akt inactivation.
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*
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Figure 2 In vivo growth of HEP2 and Detroit 562 cell lines xenografted in nude mice treated with vehicle (~), erlotinib (50mgkgday
 1 i.p.; ’),
temsirolimus (20mgkgday
 1 i.p.; m) and a combination of both (same doses;  ). The growth of the control group since the day treatment started to day
21 of the experiment was set as the reference (100%). In HEP2 xenograts erlotinib alone did not delay growth significantly, reaching 56% of the control
volume by 21 days. Temsirolimus did decrease growth to 32%, and the combination to erlotinib and temsirolimus induce a growth arrest of 22% of the
control group. However, the differences between the latter two groups were not significant. In Detroit 562, erlotinib alone delayed growth to 34% of the
control volume by 21 days. Temsirolimus slowed growth to 13%, and the combination actually induced tumour regressions. Error bars represent s.d. (n¼10
tumours per group). *Pp0.05 compared to control.
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In a separate work, two transcripts mediating mTOR expression
were identified, cyclin D1 and c-myc, which exhibited differential
expression in an Akt-dependent manner: high levels of activated
Akt resulted in rapamycin-induced downregulation of expression,
whereas low levels resulted in upregulation of expression (Gera
et al, 2004). The current report is concordant with the notion
that activation of Akt upon mTOR inhibition is a mechanism of
resistance to these agents as the HEP2 cell line in which this
phenomenon was observed was clearly resistant. As expected, the
two agents combined blunted the activation of Akt induced by
temsirolimus. Interestingly, in the cell line where erlotinib was
capable of abrogating Akt activity (Detroit 562), an at least additive
effect was observed with dual treatment; on the other hand, in
HEP2 where erlotinib had no effect on Akt the combined treatment
was equally effective as the best single agent. It can be
hypothesised that the ability of erlotinib to decrease the level of
activation of Akt is important for antitumor effect to occur.
A relevant aspect of this work is the demonstration of the value
of FNA-based pharmacodynamic assessment for the prediction of
efficacy. Fine-needle aspiration early in therapy was able to predict
in both groups the activity (or lack thereof) of the different agents
after a conventional treatment cycle; a significant decrease in all
three markers was only achieved in the sole treatment arm where
actual tumour regression was observed. Inhibition of pMAPK was
consistently seen in all four erlotinib-treated groups, but did not
correlate with growth inhibitory effect. Globally, this may indicate
that the sole assessment of a proximal marker may be inefficient to
prognosticate outcome, and combinations of several proximal and
distal markers may render better prediction results. In this work
we examined two pathway-specific proximal markers (phospho-
MAPK and phospho-P70) and a nonspecific distal marker (Ki67)
in order to comprehensively assess drug effect. We have previously
reported that proximal target inhibition is necessary but not
sufficient to achieve antitumor effect (Jimeno et al, 2005, 2006).
Interestingly, pathway assessment in vivo correlated better with
ultimate treatment efficacy than in vitro signalling. In Detroit 562,
the IHC changes were similar to those observed in the cell line
Western blots. However, in HEP2 the signalling inhibition was less
evident in vivo than in vitro, as little P70 inhibition was
documented in the tumours. This may be reflective of a more
complex environment, with multiple growth factors and stromal
interactions that are not present in vitro. It is important though
to bear in mind that none of these techniques is fully quantitative
and both have a degree of subjectivity. A combination of three IHC
markers was found to be an accurate early predictor of such
antitumor activity. This may have implications in targeted therapy
development, as new strategies consisting in sequential tumour
sampling can be implemented to predict earlier which patients
may obtain a benefit, and whom may need additional therapies
to control their tumours. This is particularly relevant in SCC of the
head and neck or cervix, where biopsies of the primary tumour
require invasive procedures not free of potentially severe
complications. On the other hand, FNA-based acquisition of
tumour material from nodal origin is feasible and safe, as is usually
coupled to ultrasound guidance and the quality and accuracy of
the procedure can be tested on site by cytopathology personnel.
It is known that mTOR inhibitors work, at least in part, by
decreasing angiogenesis (Bruns et al, 2004; Stephan et al, 2004).
Although the efficacy of mTOR inhibition and an antiangiogenic
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Figure 3 (A) The baseline levels of tumour Ki67, pMAPK and pP70
were averaged and compared with Student’s t-test. Proliferation as
assessed by Ki67 was higher in HEP2 and pMAPK was higher in Detroit
562. (B and C) Analysis and microphotographs of FNA cores. Variation in
Ki67, pMAPK and pP70 levels were assessed by means of sequential FNAs
of tumours at baseline and after 7 days of therapy. Each day 7 value was
normalised in percentage to its baseline value. Values in the Y axis represent
percentage change compared to baseline. Phospho mitogen-activated
protein kinase decreased in all four arms treated with erlotinib; in Detroit
562 the IHC changes were similar to those observed in the Figure 1
Western blots. However, in HEP2 the signalling inhibition was less evident
in vivo than in vitro, as little pP70 inhibition was documented. Indeed, pP70
only decreased significantly in Detroit 562 tumours. The only group where
a significant (X50%; cutoff arbitrarily selected) decrease in all three markers
was observed corresponded to the combination arm of Detroit 562.
wPp0.05. *Pp0.05 compared to baseline control.
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seffect have already been reported in similar SCC models
(Amornphimoltham et al, 2005), the authors presented no direct
link between these two phenomena, and hypothesised that the
decrease in the vascular network may represent a direct
consequence of the rapid reduction in the tumour size rather
than being the cause of such antitumor effect. In the presented
work, an upregulation of HIF-1a in tumours over time as their size
increased was observed, that may be secondary to an increased
hypoxia with tumour growth. In our model only dual EGFR and
mTOR inhibition was capable of preventing HIF-1a upregulation
in vivo. It has been suggested that HIF-1a is modulated by two
afferent arms, one from the EGFR pathway and other from the
PI3K/Akt pathway (Phillips et al, 2005), and we hypothesise that
only a simultaneous inhibition of both afferent arms was able to
abrogate HIF-1a. However, this observation needs to be cautiously
interpreted, as although HIF-1a downregulation was seen in both
combined arms, only in Detroit 562 there was decreased
angiogenesis. Detroit 562 tumours expressed more HIF-1a at
baseline, and also had a higher degree of increase over time with
tumour growth, as seen by the 400 vs 200% increases over 7 days in
Detroit 562 vs HEP2 tumours. This may indicate more dependence
on HIF-1a to sustain vessels growth, and thus may explain the
higher sensitivity to mTOR inhibition. Currently we do not have an
explanation for the induction of HIF-1a in the EGFR-resistant cell
line treated with erlotinib. Overexpression of proangiogenic factors
has been shown to be an acquired mechanism of resistance of A431
squamous cell line to anti-EGFR therapies (Viloria-Petit et al, 2001;
Viloria-Petit and Kerbel, 2004).
Per standard microvessel assessment, only the combination of
erlotinib and temsirolimus in Detroit 562 induced inhibition of
angiogenesis. Vessel growth followed a centripetal pattern from
the tumour capsule, likely by recruiting murine stromal cellular
components, and thus was an adequate model to test the impact of
angiogenesis inhibition. We applied a novel method that examines
the tumours in their entirety and that allowed us to examine
this external invasive pattern of vessel formation; this novel
approach correlated well with standard MVD. After breaking the
blind of the analysed samples, it was found that temsirolimus, both
alone but to a greater extent in combination with erlotinib,
was able to inhibit capillary ingrowth in Detroit 562 xenografts but
HEP2
Detroit  562
E+T E Control T
E+T E Control T
HEP2
pMAPK
Ki67
Detroit 562
HEP2
pP70
Detroit 562
C
Figure 3 (C) Continued.
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snot in HEP2 tumours. The fact that despite this absence of
antiangiogenic effect HEP2 tumours treated with temsirolimus
had a significant growth decrement suggests that mTOR inhibitors
work by multiple mechanisms as previously described. It also
implies that the antitumor effect documented in Detroit 562
xenografts may also be related to mechanisms other than
angiogenesis alone.
Cancer is the result of numerous alterations key cellular pathways
and genes (Sjoblom et al, 2006), and blocking several of these
may be necessary to achieve an antitumor effect. A reflection of this
is the success of relatively nonspecific agents such as sorafenib or of
agents that interfere at multiple levels such as bortezomib. Some
authors advocate the development of ‘magic shotguns’ rather than
‘magic bullets’ as a more realistic and potentially successful
approach to tackle a disease of such complexity as cancer (Mencher
and Wang, 2005). Combining targeted agents is another rational
strategy capable to induce tumour regressions in tumour models, as
previously reported (Jimeno et al,2 0 0 5 ) .
In summary, mTOR inhibitors showed antitumor activity in
EGFR-resistant SCC cell lines. This effect was in part mediated
by a decrease in angiogenesis. The combination with an EGFR
inhibitor induced an additive effect in one of the models. Assessing
pharmacodynamic markers by FNA-mediated biopsies early in
therapy was predictive of outcome, showing that simultaneously
inhibiting several pathways was required to induce tumour
regression. This work represents state-of-the-art targeted therapy
considering the recent approval of EGFR inhibitors in the
corresponding patient population, and addresses the unmet need
of primary or acquired resistance to such therapies.
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